AsianScientist (Jan. 13, 2014) – Navidea Biopharmaceuticals, Inc. has entered into an agreement with Global Medical Solutions Taiwan, Ltd. (GMST) to distribute the Lymphoseek® (technetium Tc 99m tilmanocept) injection in Taiwan.
The contract with GMST follows an agreement recently signed for Lymphoseek distribution in Canada. Navidea has also recently commenced shipment of Lymphoseek to select medical centers in the Middle East.
The companies will work together to address all needed Taiwanese FDA regulatory requirements and expect local approval in 2014-15. Prior to complete regulatory approval, in appropriate situations, the product will be made available in accordance with named-patient mechanisms.
The agreement anticipates distribution of non-radioactive kits as well as unit-dose product which will be radiolabeled at the GMST commercial radiopharmacy, affording flexibility in meeting the needs of end-users in the Taiwanese market.
“We are pleased to have signed our first distribution agreement for Lymphoseek in Asia with GMST,” said Dr. Thom Tulip, president and chief business officer of Navidea. “GMST provides important sales, marketing and distribution capabilities for Lymphoseek in the Taiwan market as well as providing the support needed to gain regulatory clearance in Taiwan. We believe Asia is a significant market for Lymphoseek, and Taiwan represents an important first presence as we introduce the product into the Asian communities.”
——
Source: Navidea Biopharmaceuticals Inc; Photo: stevendepolo/Flickr/CC.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
